Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study.

Although median OS was numerically higher for patients rechallenged ≥12 months after prior ICI, this difference did not reach statistical significance (34.9 versus 25.9 months; P = 0.312, log-rank test) ( Figure 2 B).

also in 111,027 other papers